[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f7l0OH2q6QrwjA23jM8APbYkKwjwFhM3jnbx-zFHE9Xw":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":37,"rows":44},"National Institute on Aging (NIA)",[4],159,false,15,19,125005,0,106,[14,17,20,22,25,28,31,34],{"name":15,"count":16},"Aging",32,{"name":18,"count":19},"Alzheimer's Disease",18,{"name":21,"count":8},"Alzheimer Disease",{"name":23,"count":24},"Obesity",12,{"name":26,"count":27},"Healthy Volunteers",9,{"name":29,"count":30},"Dementia",8,{"name":32,"count":33},"Atherosclerosis",7,{"name":35,"count":33},"Diabetes",[],[38,39,40,41,42,43],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[45,82,110,135,153,178,216,238,256,277,300,318,345,370,394,416,434,457,480,498,516,540,562,599,637,661,687,705,729,747,769,797,815,840,865,883,920,949,974,997,1015,1036,1059,1083,1106,1130,1153,1171,1189,1214,1232,1250,1268,1294,1312,1337,1355,1373,1409,1442,1469,1503,1526,1548,1571,1599,1617],{"intervention":46,"totalTrials":47,"cells":48},"Donepezil",2,{"EARLY_PHASE1":49,"PHASE1":51,"PHASE2":53,"PHASE3":55,"PHASE4":67,"NA":80},{"trials":50,"activeCount":11},[],{"trials":52,"activeCount":11},[],{"trials":54,"activeCount":11},[],{"trials":56,"activeCount":11},[57],{"nctId":58,"briefTitle":59,"status":60,"phases":61,"primaryCompletion":62,"completion":62,"start":63,"conditions":64,"interventions":65},"NCT00000173","Memory Impairment Study (Mild Cognitive Impairment Study)","COMPLETED",[41],"2004-01","1999-03",[21],[46,66],"Vitamin E",{"trials":68,"activeCount":11},[69],{"nctId":70,"briefTitle":71,"status":60,"phases":72,"primaryCompletion":73,"completion":73,"start":74,"enrollment":75,"conditions":76,"interventions":78},"NCT00267163","Brain Imaging and Mental Disorders of Aging Intervention",[42],"2007-07","2000-09",64,[77],"Cognition Disorders",[79],"donepezil",{"trials":81,"activeCount":11},[],{"intervention":83,"totalTrials":84,"cells":85},"Digoxin immune fab",1,{"EARLY_PHASE1":86,"PHASE1":88,"PHASE2":90,"PHASE3":92,"PHASE4":94,"NA":108},{"trials":87,"activeCount":11},[],{"trials":89,"activeCount":11},[],{"trials":91,"activeCount":11},[],{"trials":93,"activeCount":11},[],{"trials":95,"activeCount":11},[96],{"nctId":97,"briefTitle":98,"status":99,"phases":100,"primaryCompletion":101,"completion":101,"start":102,"enrollment":103,"conditions":104,"interventions":107},"NCT00852787","Marinobufagenin as a Target for DIGIBIND in Hypertensive Patients With End-stage Renal Disease","UNKNOWN",[42],"2012-05","2009-04",30,[105,106],"Hypertension","Hemodialysis",[83],{"trials":109,"activeCount":11},[],{"intervention":111,"totalTrials":84,"cells":112},"Pneumococcal Vaccine",{"EARLY_PHASE1":113,"PHASE1":115,"PHASE2":117,"PHASE3":119,"PHASE4":121,"NA":133},{"trials":114,"activeCount":11},[],{"trials":116,"activeCount":11},[],{"trials":118,"activeCount":11},[],{"trials":120,"activeCount":11},[],{"trials":122,"activeCount":11},[123],{"nctId":124,"briefTitle":125,"status":60,"phases":126,"primaryCompletion":127,"completion":127,"start":128,"enrollment":129,"conditions":130,"interventions":131},"NCT00239694","PPV: Pneumococcal Polysaccharide Vaccine in Older Adults",[42],"2012-08","2001-04",100,[15],[111,132],"Meningococcal Vaccine",{"trials":134,"activeCount":11},[],{"intervention":132,"totalTrials":84,"cells":136},{"EARLY_PHASE1":137,"PHASE1":139,"PHASE2":141,"PHASE3":143,"PHASE4":145,"NA":151},{"trials":138,"activeCount":11},[],{"trials":140,"activeCount":11},[],{"trials":142,"activeCount":11},[],{"trials":144,"activeCount":11},[],{"trials":146,"activeCount":11},[147],{"nctId":124,"briefTitle":125,"status":60,"phases":148,"primaryCompletion":127,"completion":127,"start":128,"enrollment":129,"conditions":149,"interventions":150},[42],[15],[111,132],{"trials":152,"activeCount":11},[],{"intervention":154,"totalTrials":84,"cells":155},"Quetiapine",{"EARLY_PHASE1":156,"PHASE1":158,"PHASE2":160,"PHASE3":162,"PHASE4":164,"NA":176},{"trials":157,"activeCount":11},[],{"trials":159,"activeCount":11},[],{"trials":161,"activeCount":11},[],{"trials":163,"activeCount":11},[],{"trials":165,"activeCount":11},[166],{"nctId":167,"briefTitle":168,"status":60,"phases":169,"primaryCompletion":170,"completion":170,"start":171,"enrollment":172,"conditions":173,"interventions":175},"NCT00043849","Treatment of Agitation\u002FPsychosis in Dementia\u002FParkinsonism (TAP\u002FDAP)",[42],"2005-06","2002-07",60,[29,174],"Parkinson Disease",[154],{"trials":177,"activeCount":11},[],{"intervention":179,"totalTrials":47,"cells":180},"vitamin B12",{"EARLY_PHASE1":181,"PHASE1":183,"PHASE2":185,"PHASE3":187,"PHASE4":212,"NA":214},{"trials":182,"activeCount":11},[],{"trials":184,"activeCount":11},[],{"trials":186,"activeCount":11},[],{"trials":188,"activeCount":11},[189,200],{"nctId":190,"briefTitle":191,"status":60,"phases":192,"primaryCompletion":193,"completion":193,"start":194,"enrollment":195,"conditions":196,"interventions":197},"NCT00114400","BVAIT: B-Vitamin Atherosclerosis Intervention Trial",[40,41],"2007-02","2000-11",506,[32],[198,179,199],"folic acid","vitamin B6",{"nctId":201,"briefTitle":202,"status":60,"phases":203,"primaryCompletion":204,"completion":204,"start":205,"enrollment":206,"conditions":207,"interventions":208},"NCT00056225","VITAL - VITamins to Slow ALzheimer's Disease (Homocysteine Study)",[41],"2007-06","2003-01",340,[18],[209,210,211],"Folate","Vitamin B6","Vitamin B12",{"trials":213,"activeCount":11},[],{"trials":215,"activeCount":11},[],{"intervention":199,"totalTrials":47,"cells":217},{"EARLY_PHASE1":218,"PHASE1":220,"PHASE2":222,"PHASE3":224,"PHASE4":234,"NA":236},{"trials":219,"activeCount":11},[],{"trials":221,"activeCount":11},[],{"trials":223,"activeCount":11},[],{"trials":225,"activeCount":11},[226,230],{"nctId":190,"briefTitle":191,"status":60,"phases":227,"primaryCompletion":193,"completion":193,"start":194,"enrollment":195,"conditions":228,"interventions":229},[40,41],[32],[198,179,199],{"nctId":201,"briefTitle":202,"status":60,"phases":231,"primaryCompletion":204,"completion":204,"start":205,"enrollment":206,"conditions":232,"interventions":233},[41],[18],[209,210,211],{"trials":235,"activeCount":11},[],{"trials":237,"activeCount":11},[],{"intervention":66,"totalTrials":84,"cells":239},{"EARLY_PHASE1":240,"PHASE1":242,"PHASE2":244,"PHASE3":246,"PHASE4":252,"NA":254},{"trials":241,"activeCount":11},[],{"trials":243,"activeCount":11},[],{"trials":245,"activeCount":11},[],{"trials":247,"activeCount":11},[248],{"nctId":58,"briefTitle":59,"status":60,"phases":249,"primaryCompletion":62,"completion":62,"start":63,"conditions":250,"interventions":251},[41],[21],[46,66],{"trials":253,"activeCount":11},[],{"trials":255,"activeCount":11},[],{"intervention":257,"totalTrials":84,"cells":258},"Prednisone",{"EARLY_PHASE1":259,"PHASE1":261,"PHASE2":263,"PHASE3":265,"PHASE4":273,"NA":275},{"trials":260,"activeCount":11},[],{"trials":262,"activeCount":11},[],{"trials":264,"activeCount":11},[],{"trials":266,"activeCount":11},[267],{"nctId":268,"briefTitle":269,"status":60,"phases":270,"conditions":271,"interventions":272},"NCT00000178","Multicenter Trial of Prednisone in Alzheimer's Disease",[41],[21],[257],{"trials":274,"activeCount":11},[],{"trials":276,"activeCount":11},[],{"intervention":278,"totalTrials":84,"cells":279},"DL-alpha-tocopherol",{"EARLY_PHASE1":280,"PHASE1":282,"PHASE2":284,"PHASE3":286,"PHASE4":296,"NA":298},{"trials":281,"activeCount":11},[],{"trials":283,"activeCount":11},[],{"trials":285,"activeCount":11},[],{"trials":287,"activeCount":11},[288],{"nctId":289,"briefTitle":290,"status":60,"phases":291,"primaryCompletion":74,"completion":74,"start":292,"enrollment":293,"conditions":294,"interventions":295},"NCT00114387","VEAPS: Vitamin E Atherosclerosis Prevention Study",[40,41],"1996-07",353,[32],[278],{"trials":297,"activeCount":11},[],{"trials":299,"activeCount":11},[],{"intervention":198,"totalTrials":84,"cells":301},{"EARLY_PHASE1":302,"PHASE1":304,"PHASE2":306,"PHASE3":308,"PHASE4":314,"NA":316},{"trials":303,"activeCount":11},[],{"trials":305,"activeCount":11},[],{"trials":307,"activeCount":11},[],{"trials":309,"activeCount":11},[310],{"nctId":190,"briefTitle":191,"status":60,"phases":311,"primaryCompletion":193,"completion":193,"start":194,"enrollment":195,"conditions":312,"interventions":313},[40,41],[32],[198,179,199],{"trials":315,"activeCount":11},[],{"trials":317,"activeCount":11},[],{"intervention":319,"totalTrials":84,"cells":320},"Vitamin K",{"EARLY_PHASE1":321,"PHASE1":323,"PHASE2":325,"PHASE3":327,"PHASE4":341,"NA":343},{"trials":322,"activeCount":11},[],{"trials":324,"activeCount":11},[],{"trials":326,"activeCount":11},[],{"trials":328,"activeCount":11},[329],{"nctId":330,"briefTitle":331,"status":60,"phases":332,"completion":333,"start":334,"enrollment":335,"conditions":336,"interventions":340},"NCT00183001","Effect of Vitamin K on Age-Related Bone Loss and Vascular Calcification",[41],"2006-10","2001-10",452,[337,338,339],"Osteoporosis","Vascular Calcification","Inflammation",[319],{"trials":342,"activeCount":11},[],{"trials":344,"activeCount":11},[],{"intervention":346,"totalTrials":84,"cells":347},"Micronized 17B-estradiol",{"EARLY_PHASE1":348,"PHASE1":350,"PHASE2":352,"PHASE3":354,"PHASE4":366,"NA":368},{"trials":349,"activeCount":11},[],{"trials":351,"activeCount":11},[],{"trials":353,"activeCount":11},[],{"trials":355,"activeCount":11},[356],{"nctId":357,"briefTitle":358,"status":60,"phases":359,"primaryCompletion":360,"completion":360,"start":361,"enrollment":362,"conditions":363,"interventions":365},"NCT00115024","EPAT: Estrogen in the Prevention of Atherosclerosis Trial",[40,41],"1998-11","1994-04",222,[32,364],"Postmenopause",[346],{"trials":367,"activeCount":11},[],{"trials":369,"activeCount":11},[],{"intervention":371,"totalTrials":84,"cells":372},"Estrogen and Progesterone",{"EARLY_PHASE1":373,"PHASE1":375,"PHASE2":377,"PHASE3":379,"PHASE4":390,"NA":392},{"trials":374,"activeCount":11},[],{"trials":376,"activeCount":11},[],{"trials":378,"activeCount":11},[],{"trials":380,"activeCount":11},[381],{"nctId":382,"briefTitle":383,"status":60,"phases":384,"primaryCompletion":385,"completion":385,"conditions":386,"interventions":388},"NCT00000176","Alzheimer's Disease Prevention Trial",[41],"2007-09",[21,387],"Memory Disorders",[389,371],"Estrogen",{"trials":391,"activeCount":11},[],{"trials":393,"activeCount":11},[],{"intervention":395,"totalTrials":84,"cells":396},"Trazodone",{"EARLY_PHASE1":397,"PHASE1":399,"PHASE2":401,"PHASE3":403,"PHASE4":412,"NA":414},{"trials":398,"activeCount":11},[],{"trials":400,"activeCount":11},[],{"trials":402,"activeCount":11},[],{"trials":404,"activeCount":11},[405],{"nctId":406,"briefTitle":407,"status":60,"phases":408,"conditions":409,"interventions":410},"NCT00000179","Agitation in Alzheimer's Disease",[41],[21],[395,411],"Haloperidol",{"trials":413,"activeCount":11},[],{"trials":415,"activeCount":11},[],{"intervention":411,"totalTrials":84,"cells":417},{"EARLY_PHASE1":418,"PHASE1":420,"PHASE2":422,"PHASE3":424,"PHASE4":430,"NA":432},{"trials":419,"activeCount":11},[],{"trials":421,"activeCount":11},[],{"trials":423,"activeCount":11},[],{"trials":425,"activeCount":11},[426],{"nctId":406,"briefTitle":407,"status":60,"phases":427,"conditions":428,"interventions":429},[41],[21],[395,411],{"trials":431,"activeCount":11},[],{"trials":433,"activeCount":11},[],{"intervention":435,"totalTrials":84,"cells":436},"DHEA replacement",{"EARLY_PHASE1":437,"PHASE1":439,"PHASE2":441,"PHASE3":443,"PHASE4":453,"NA":455},{"trials":438,"activeCount":11},[],{"trials":440,"activeCount":11},[],{"trials":442,"activeCount":11},[],{"trials":444,"activeCount":11},[445],{"nctId":446,"briefTitle":447,"status":60,"phases":448,"primaryCompletion":385,"completion":385,"start":449,"enrollment":450,"conditions":451,"interventions":452},"NCT00182975","Effects of Dehydroepiandrosterone (DHEA) in Humans",[41],"2002-09",142,[15],[435],{"trials":454,"activeCount":11},[],{"trials":456,"activeCount":11},[],{"intervention":458,"totalTrials":84,"cells":459},"Rofecoxib",{"EARLY_PHASE1":460,"PHASE1":462,"PHASE2":464,"PHASE3":466,"PHASE4":476,"NA":478},{"trials":461,"activeCount":11},[],{"trials":463,"activeCount":11},[],{"trials":465,"activeCount":11},[],{"trials":467,"activeCount":11},[468],{"nctId":469,"briefTitle":470,"status":60,"phases":471,"primaryCompletion":472,"completion":472,"conditions":473,"interventions":474},"NCT00004845","A Multicenter Trial of Rofecoxib and Naproxen in Alzheimer's Disease (NSAID Study)",[40,41],"2001-12",[21],[458,475],"Naproxen",{"trials":477,"activeCount":11},[],{"trials":479,"activeCount":11},[],{"intervention":475,"totalTrials":84,"cells":481},{"EARLY_PHASE1":482,"PHASE1":484,"PHASE2":486,"PHASE3":488,"PHASE4":494,"NA":496},{"trials":483,"activeCount":11},[],{"trials":485,"activeCount":11},[],{"trials":487,"activeCount":11},[],{"trials":489,"activeCount":11},[490],{"nctId":469,"briefTitle":470,"status":60,"phases":491,"primaryCompletion":472,"completion":472,"conditions":492,"interventions":493},[40,41],[21],[458,475],{"trials":495,"activeCount":11},[],{"trials":497,"activeCount":11},[],{"intervention":209,"totalTrials":84,"cells":499},{"EARLY_PHASE1":500,"PHASE1":502,"PHASE2":504,"PHASE3":506,"PHASE4":512,"NA":514},{"trials":501,"activeCount":11},[],{"trials":503,"activeCount":11},[],{"trials":505,"activeCount":11},[],{"trials":507,"activeCount":11},[508],{"nctId":201,"briefTitle":202,"status":60,"phases":509,"primaryCompletion":204,"completion":204,"start":205,"enrollment":206,"conditions":510,"interventions":511},[41],[18],[209,210,211],{"trials":513,"activeCount":11},[],{"trials":515,"activeCount":11},[],{"intervention":517,"totalTrials":84,"cells":518},"Simvastatin",{"EARLY_PHASE1":519,"PHASE1":521,"PHASE2":523,"PHASE3":525,"PHASE4":536,"NA":538},{"trials":520,"activeCount":11},[],{"trials":522,"activeCount":11},[],{"trials":524,"activeCount":11},[],{"trials":526,"activeCount":11},[527],{"nctId":528,"briefTitle":529,"status":60,"phases":530,"primaryCompletion":531,"completion":531,"start":532,"enrollment":533,"conditions":534,"interventions":535},"NCT00053599","Cholesterol Lowering Agent to Slow Progression (CLASP) of Alzheimer's Disease Study",[41],"2007-10","2002-12",400,[21],[517],{"trials":537,"activeCount":11},[],{"trials":539,"activeCount":11},[],{"intervention":541,"totalTrials":84,"cells":542},"Melatonin",{"EARLY_PHASE1":543,"PHASE1":545,"PHASE2":547,"PHASE3":549,"PHASE4":558,"NA":560},{"trials":544,"activeCount":11},[],{"trials":546,"activeCount":11},[],{"trials":548,"activeCount":11},[],{"trials":550,"activeCount":11},[551],{"nctId":552,"briefTitle":553,"status":60,"phases":554,"conditions":555,"interventions":557},"NCT00000171","Study of Melatonin: Sleep Problems in Alzheimer's Disease",[41],[21,556],"Dyssomnias",[541],{"trials":559,"activeCount":11},[],{"trials":561,"activeCount":11},[],{"intervention":563,"totalTrials":47,"cells":564},"Epoetin alfa",{"EARLY_PHASE1":565,"PHASE1":567,"PHASE2":569,"PHASE3":593,"PHASE4":595,"NA":597},{"trials":566,"activeCount":11},[],{"trials":568,"activeCount":11},[],{"trials":570,"activeCount":11},[571,582],{"nctId":572,"briefTitle":573,"status":60,"phases":574,"primaryCompletion":575,"completion":576,"start":577,"enrollment":578,"conditions":579,"interventions":581},"NCT00378352","REVEAL: Reduction of Infarct Expansion and Ventricular Remodeling With Erythropoietin After Large Myocardial Infarction",[40],"2009-07","2011-01","2005-09",223,[580],"Acute ST Elevation Myocardial Infarction",[563],{"nctId":583,"briefTitle":584,"status":585,"phases":586,"primaryCompletion":587,"completion":587,"start":588,"enrollment":11,"conditions":589,"interventions":591},"NCT00104169","Idiopathic Anemia of Aging (IAA)","TERMINATED",[40],"2007-05","2004-08",[590,15],"Anemia",[592],"Epoetin Alfa",{"trials":594,"activeCount":11},[],{"trials":596,"activeCount":11},[],{"trials":598,"activeCount":11},[],{"intervention":600,"totalTrials":47,"cells":601},"bryostatin 1",{"EARLY_PHASE1":602,"PHASE1":604,"PHASE2":619,"PHASE3":631,"PHASE4":633,"NA":635},{"trials":603,"activeCount":11},[],{"trials":605,"activeCount":11},[606],{"nctId":607,"briefTitle":608,"status":60,"phases":609,"primaryCompletion":610,"start":611,"enrollment":612,"conditions":613,"interventions":617},"NCT00003993","Bryostatin 1 and Interleukin-2 in Treating Patients With Refractory Solid Tumors or Lymphoma",[39],"2008-07","1999-09",24,[614,615,616],"Lymphoma","Small Intestine Cancer","Unspecified Adult Solid Tumor, Protocol Specific",[618,600],"aldesleukin",{"trials":620,"activeCount":11},[621],{"nctId":622,"briefTitle":623,"status":60,"phases":624,"primaryCompletion":531,"start":625,"enrollment":626,"conditions":627,"interventions":629},"NCT00087425","Bryostatin 1 and Rituximab in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia",[40],"2004-07",48,[628,614],"Leukemia",[630,600],"rituximab",{"trials":632,"activeCount":11},[],{"trials":634,"activeCount":11},[],{"trials":636,"activeCount":11},[],{"intervention":638,"totalTrials":84,"cells":639},"Huperzine A",{"EARLY_PHASE1":640,"PHASE1":642,"PHASE2":644,"PHASE3":655,"PHASE4":657,"NA":659},{"trials":641,"activeCount":11},[],{"trials":643,"activeCount":11},[],{"trials":645,"activeCount":11},[646],{"nctId":647,"briefTitle":648,"status":60,"phases":649,"primaryCompletion":650,"completion":650,"start":651,"enrollment":652,"conditions":653,"interventions":654},"NCT00083590","Huperzine A in Alzheimer's Disease",[40],"2007-11","2004-04",150,[21],[638],{"trials":656,"activeCount":11},[],{"trials":658,"activeCount":11},[],{"trials":660,"activeCount":11},[],{"intervention":662,"totalTrials":84,"cells":663},"Topical testosterone",{"EARLY_PHASE1":664,"PHASE1":666,"PHASE2":668,"PHASE3":681,"PHASE4":683,"NA":685},{"trials":665,"activeCount":11},[],{"trials":667,"activeCount":11},[],{"trials":669,"activeCount":11},[670],{"nctId":671,"briefTitle":672,"status":60,"phases":673,"primaryCompletion":193,"completion":193,"start":449,"enrollment":674,"conditions":675,"interventions":679},"NCT00183040","HORMA: Hormonal Regulators of Muscle and Metabolism in Aging",[40],108,[676,677,678],"Sarcopenia","Muscle Weakness","Frailty",[662,680],"Recombinant human growth hormone",{"trials":682,"activeCount":11},[],{"trials":684,"activeCount":11},[],{"trials":686,"activeCount":11},[],{"intervention":680,"totalTrials":84,"cells":688},{"EARLY_PHASE1":689,"PHASE1":691,"PHASE2":693,"PHASE3":699,"PHASE4":701,"NA":703},{"trials":690,"activeCount":11},[],{"trials":692,"activeCount":11},[],{"trials":694,"activeCount":11},[695],{"nctId":671,"briefTitle":672,"status":60,"phases":696,"primaryCompletion":193,"completion":193,"start":449,"enrollment":674,"conditions":697,"interventions":698},[40],[676,677,678],[662,680],{"trials":700,"activeCount":11},[],{"trials":702,"activeCount":11},[],{"trials":704,"activeCount":11},[],{"intervention":706,"totalTrials":84,"cells":707},"conjugated estrogens",{"EARLY_PHASE1":708,"PHASE1":710,"PHASE2":712,"PHASE3":723,"PHASE4":725,"NA":727},{"trials":709,"activeCount":11},[],{"trials":711,"activeCount":11},[],{"trials":713,"activeCount":11},[714],{"nctId":715,"briefTitle":716,"status":60,"phases":717,"primaryCompletion":718,"completion":718,"start":719,"enrollment":674,"conditions":720,"interventions":721},"NCT00149604","AFTER: Altering Fat Through Estrogen and Raloxifene",[40],"2006-02","2000-03",[364],[706,722],"Raloxifene",{"trials":724,"activeCount":11},[],{"trials":726,"activeCount":11},[],{"trials":728,"activeCount":11},[],{"intervention":722,"totalTrials":84,"cells":730},{"EARLY_PHASE1":731,"PHASE1":733,"PHASE2":735,"PHASE3":741,"PHASE4":743,"NA":745},{"trials":732,"activeCount":11},[],{"trials":734,"activeCount":11},[],{"trials":736,"activeCount":11},[737],{"nctId":715,"briefTitle":716,"status":60,"phases":738,"primaryCompletion":718,"completion":718,"start":719,"enrollment":674,"conditions":739,"interventions":740},[40],[364],[706,722],{"trials":742,"activeCount":11},[],{"trials":744,"activeCount":11},[],{"trials":746,"activeCount":11},[],{"intervention":748,"totalTrials":84,"cells":749},"Nutritional Supplement",{"EARLY_PHASE1":750,"PHASE1":752,"PHASE2":754,"PHASE3":763,"PHASE4":765,"NA":767},{"trials":751,"activeCount":11},[],{"trials":753,"activeCount":11},[],{"trials":755,"activeCount":11},[756],{"nctId":757,"briefTitle":758,"status":60,"phases":759,"primaryCompletion":170,"completion":170,"enrollment":760,"conditions":761,"interventions":762},"NCT00013923","Effectiveness of A Nutritional Brain Metabolic Enhancer for Alzheimer Disease",[40],40,[21],[748],{"trials":764,"activeCount":11},[],{"trials":766,"activeCount":11},[],{"trials":768,"activeCount":11},[],{"intervention":770,"totalTrials":84,"cells":771},"Androgel",{"EARLY_PHASE1":772,"PHASE1":774,"PHASE2":776,"PHASE3":791,"PHASE4":793,"NA":795},{"trials":773,"activeCount":11},[],{"trials":775,"activeCount":11},[],{"trials":777,"activeCount":11},[778],{"nctId":779,"briefTitle":780,"status":60,"phases":781,"primaryCompletion":782,"completion":783,"start":784,"enrollment":785,"conditions":786,"interventions":789},"NCT00104572","Effects of Aromatase Inhibition Versus Testosterone in Older Men With Low Testosterone: Randomized-Controlled Trial.",[40],"2013-12","2015-01","2004-03",44,[787,35,676,337,788],"Hypogonadism","Depression",[770,790],"Anastrozole",{"trials":792,"activeCount":11},[],{"trials":794,"activeCount":11},[],{"trials":796,"activeCount":11},[],{"intervention":790,"totalTrials":84,"cells":798},{"EARLY_PHASE1":799,"PHASE1":801,"PHASE2":803,"PHASE3":809,"PHASE4":811,"NA":813},{"trials":800,"activeCount":11},[],{"trials":802,"activeCount":11},[],{"trials":804,"activeCount":11},[805],{"nctId":779,"briefTitle":780,"status":60,"phases":806,"primaryCompletion":782,"completion":783,"start":784,"enrollment":785,"conditions":807,"interventions":808},[40],[787,35,676,337,788],[770,790],{"trials":810,"activeCount":11},[],{"trials":812,"activeCount":11},[],{"trials":814,"activeCount":11},[],{"intervention":816,"totalTrials":84,"cells":817},"Exendin-4 SC",{"EARLY_PHASE1":818,"PHASE1":820,"PHASE2":822,"PHASE3":834,"PHASE4":836,"NA":838},{"trials":819,"activeCount":11},[],{"trials":821,"activeCount":11},[],{"trials":823,"activeCount":11},[824],{"nctId":825,"briefTitle":826,"status":585,"phases":827,"primaryCompletion":828,"completion":828,"start":829,"enrollment":830,"conditions":831,"interventions":833},"NCT01255163","A Pilot Clinical Trial of Exendin-4 in Alzheimer's Disease",[40],"2016-11-18","2010-11-21",57,[18,832],"Mild Cognitive Impairment",[816],{"trials":835,"activeCount":11},[],{"trials":837,"activeCount":11},[],{"trials":839,"activeCount":11},[],{"intervention":841,"totalTrials":84,"cells":842},"Metformin",{"EARLY_PHASE1":843,"PHASE1":845,"PHASE2":847,"PHASE3":859,"PHASE4":861,"NA":863},{"trials":844,"activeCount":11},[],{"trials":846,"activeCount":11},[],{"trials":848,"activeCount":11},[849],{"nctId":850,"briefTitle":851,"status":60,"phases":852,"primaryCompletion":853,"completion":853,"start":62,"enrollment":854,"conditions":855,"interventions":858},"NCT00105066","The Effects of Metformin on Blood Vessel Structure and Function",[40],"2008-05",77,[23,105,856,857],"Hypercholesterolemia","Hyperglycemia",[841],{"trials":860,"activeCount":11},[],{"trials":862,"activeCount":11},[],{"trials":864,"activeCount":11},[],{"intervention":630,"totalTrials":84,"cells":866},{"EARLY_PHASE1":867,"PHASE1":869,"PHASE2":871,"PHASE3":877,"PHASE4":879,"NA":881},{"trials":868,"activeCount":11},[],{"trials":870,"activeCount":11},[],{"trials":872,"activeCount":11},[873],{"nctId":622,"briefTitle":623,"status":60,"phases":874,"primaryCompletion":531,"start":625,"enrollment":626,"conditions":875,"interventions":876},[40],[628,614],[630,600],{"trials":878,"activeCount":11},[],{"trials":880,"activeCount":11},[],{"trials":882,"activeCount":11},[],{"intervention":884,"totalTrials":47,"cells":885},"Normal Saline",{"EARLY_PHASE1":886,"PHASE1":888,"PHASE2":912,"PHASE3":914,"PHASE4":916,"NA":918},{"trials":887,"activeCount":11},[],{"trials":889,"activeCount":11},[890,902],{"nctId":891,"briefTitle":892,"status":60,"phases":893,"primaryCompletion":894,"completion":894,"start":895,"enrollment":896,"conditions":897,"interventions":899},"NCT00239707","GIP: Glucose-dependent Insulinotropic Peptide",[39],"2006-12","2003-02",41,[898],"Type 2 Diabetes",[900,901,884],"GIP","Modified GIP",{"nctId":903,"briefTitle":904,"status":60,"phases":905,"primaryCompletion":127,"completion":127,"start":906,"enrollment":612,"conditions":907,"interventions":909},"NCT00251602","Analysis of Atropine and Propranolol Induced Changes",[39],"2003-03",[908],"Healthy",[910,911,884],"Atropine","Propranolol",{"trials":913,"activeCount":11},[],{"trials":915,"activeCount":11},[],{"trials":917,"activeCount":11},[],{"trials":919,"activeCount":11},[],{"intervention":921,"totalTrials":84,"cells":922},"empagliflozin (Jardiance) 25 mg",{"EARLY_PHASE1":923,"PHASE1":925,"PHASE2":941,"PHASE3":943,"PHASE4":945,"NA":947},{"trials":924,"activeCount":11},[],{"trials":926,"activeCount":11},[927],{"nctId":928,"briefTitle":929,"status":60,"phases":930,"primaryCompletion":931,"completion":932,"start":933,"enrollment":934,"conditions":935,"interventions":940},"NCT03852901","Sodium-glucose Co Transporter 2 (sGLT2) Inhibitor and Endogenous Ketone Production",[39],"2020-11-12","2021-12-13","2019-03-28",21,[936,937,938,939],"Empaglifozin","Physiological Effects of Drugs","Hypoglycemic Agents","Sodium-Glucose Transporter 2 Inhibitors",[921],{"trials":942,"activeCount":11},[],{"trials":944,"activeCount":11},[],{"trials":946,"activeCount":11},[],{"trials":948,"activeCount":11},[],{"intervention":950,"totalTrials":84,"cells":951},"BNC",{"EARLY_PHASE1":952,"PHASE1":954,"PHASE2":966,"PHASE3":968,"PHASE4":970,"NA":972},{"trials":953,"activeCount":11},[],{"trials":955,"activeCount":11},[956],{"nctId":957,"briefTitle":958,"status":60,"phases":959,"primaryCompletion":960,"completion":961,"start":962,"enrollment":963,"conditions":964,"interventions":965},"NCT01747213","Bisnorcymserine in Healthy Adult Volunteers",[39],"2018-09-21","2019-01-08","2013-01-29",75,[26],[950],{"trials":967,"activeCount":11},[],{"trials":969,"activeCount":11},[],{"trials":971,"activeCount":11},[],{"trials":973,"activeCount":11},[],{"intervention":975,"totalTrials":84,"cells":976},"Vitamin E, Vitamin C, and Alpha-lipoic Acid",{"EARLY_PHASE1":977,"PHASE1":979,"PHASE2":989,"PHASE3":991,"PHASE4":993,"NA":995},{"trials":978,"activeCount":11},[],{"trials":980,"activeCount":11},[981],{"nctId":982,"briefTitle":983,"status":60,"phases":984,"primaryCompletion":385,"completion":385,"start":985,"enrollment":963,"conditions":986,"interventions":987},"NCT00117403","Anti-Oxidant Treatment of Alzheimer's Disease",[39],"2006-01",[18],[975,988],"Coenzyme Q",{"trials":990,"activeCount":11},[],{"trials":992,"activeCount":11},[],{"trials":994,"activeCount":11},[],{"trials":996,"activeCount":11},[],{"intervention":988,"totalTrials":84,"cells":998},{"EARLY_PHASE1":999,"PHASE1":1001,"PHASE2":1007,"PHASE3":1009,"PHASE4":1011,"NA":1013},{"trials":1000,"activeCount":11},[],{"trials":1002,"activeCount":11},[1003],{"nctId":982,"briefTitle":983,"status":60,"phases":1004,"primaryCompletion":385,"completion":385,"start":985,"enrollment":963,"conditions":1005,"interventions":1006},[39],[18],[975,988],{"trials":1008,"activeCount":11},[],{"trials":1010,"activeCount":11},[],{"trials":1012,"activeCount":11},[],{"trials":1014,"activeCount":11},[],{"intervention":1016,"totalTrials":84,"cells":1017},"AIT-082",{"EARLY_PHASE1":1018,"PHASE1":1020,"PHASE2":1028,"PHASE3":1030,"PHASE4":1032,"NA":1034},{"trials":1019,"activeCount":11},[],{"trials":1021,"activeCount":11},[1022],{"nctId":1023,"briefTitle":1024,"status":60,"phases":1025,"primaryCompletion":170,"completion":170,"conditions":1026,"interventions":1027},"NCT00000180","AIT-082 Phase 1B Study",[39],[387],[1016],{"trials":1029,"activeCount":11},[],{"trials":1031,"activeCount":11},[],{"trials":1033,"activeCount":11},[],{"trials":1035,"activeCount":11},[],{"intervention":1037,"totalTrials":84,"cells":1038},"Ibuprofen",{"EARLY_PHASE1":1039,"PHASE1":1041,"PHASE2":1051,"PHASE3":1053,"PHASE4":1055,"NA":1057},{"trials":1040,"activeCount":11},[],{"trials":1042,"activeCount":11},[1043],{"nctId":1044,"briefTitle":1045,"status":99,"phases":1046,"primaryCompletion":1047,"completion":1047,"start":1048,"enrollment":760,"conditions":1049,"interventions":1050},"NCT00239746","BONSAI: Biomarkers of Nonsteroidal Anti-Inflammatories",[39],"2009-08","2005-10",[18],[1037],{"trials":1052,"activeCount":11},[],{"trials":1054,"activeCount":11},[],{"trials":1056,"activeCount":11},[],{"trials":1058,"activeCount":11},[],{"intervention":1060,"totalTrials":84,"cells":1061},"Norditropin",{"EARLY_PHASE1":1062,"PHASE1":1064,"PHASE2":1075,"PHASE3":1077,"PHASE4":1079,"NA":1081},{"trials":1063,"activeCount":11},[],{"trials":1065,"activeCount":11},[1066],{"nctId":1067,"briefTitle":1068,"status":60,"phases":1069,"primaryCompletion":1070,"completion":1070,"start":1071,"enrollment":1072,"conditions":1073,"interventions":1074},"NCT00663611","Growth Hormone Administration and the Human Immune System",[39],"2014-10-06","2006-10-19",66,[26],[1060],{"trials":1076,"activeCount":11},[],{"trials":1078,"activeCount":11},[],{"trials":1080,"activeCount":11},[],{"trials":1082,"activeCount":11},[],{"intervention":1084,"totalTrials":84,"cells":1085},"CP-945,598",{"EARLY_PHASE1":1086,"PHASE1":1088,"PHASE2":1098,"PHASE3":1100,"PHASE4":1102,"NA":1104},{"trials":1087,"activeCount":11},[],{"trials":1089,"activeCount":11},[1090],{"nctId":1091,"briefTitle":1092,"status":60,"phases":1093,"primaryCompletion":1070,"completion":1070,"start":1094,"enrollment":1095,"conditions":1096,"interventions":1097},"NCT01517100","The Role of Endocannabinoids in Insulin Production and Action",[39],"2012-01-05",45,[26],[1084],{"trials":1099,"activeCount":11},[],{"trials":1101,"activeCount":11},[],{"trials":1103,"activeCount":11},[],{"trials":1105,"activeCount":11},[],{"intervention":1107,"totalTrials":84,"cells":1108},"Biotin RBC survival",{"EARLY_PHASE1":1109,"PHASE1":1111,"PHASE2":1122,"PHASE3":1124,"PHASE4":1126,"NA":1128},{"trials":1110,"activeCount":11},[],{"trials":1112,"activeCount":11},[1113],{"nctId":1114,"briefTitle":1115,"status":60,"phases":1116,"primaryCompletion":1117,"completion":1117,"start":1118,"enrollment":1119,"conditions":1120,"interventions":1121},"NCT01572506","Mechanisms Accounting for Unexplained Anemia in the Elderly",[39],"2015-07-30","2012-03-29",58,[590],[1107],{"trials":1123,"activeCount":11},[],{"trials":1125,"activeCount":11},[],{"trials":1127,"activeCount":11},[],{"trials":1129,"activeCount":11},[],{"intervention":1131,"totalTrials":84,"cells":1132},"Transdermal nicotine patch",{"EARLY_PHASE1":1133,"PHASE1":1135,"PHASE2":1145,"PHASE3":1147,"PHASE4":1149,"NA":1151},{"trials":1134,"activeCount":11},[],{"trials":1136,"activeCount":11},[1137],{"nctId":1138,"briefTitle":1139,"status":99,"phases":1140,"primaryCompletion":610,"completion":610,"start":1141,"enrollment":963,"conditions":1142,"interventions":1144},"NCT00091468","Nicotine Treatment of Mild Cognitive Impairment (MCI)",[39],"2003-09",[1143],"Age-Related Memory Disorders",[1131],{"trials":1146,"activeCount":11},[],{"trials":1148,"activeCount":11},[],{"trials":1150,"activeCount":11},[],{"trials":1152,"activeCount":11},[],{"intervention":900,"totalTrials":84,"cells":1154},{"EARLY_PHASE1":1155,"PHASE1":1157,"PHASE2":1163,"PHASE3":1165,"PHASE4":1167,"NA":1169},{"trials":1156,"activeCount":11},[],{"trials":1158,"activeCount":11},[1159],{"nctId":891,"briefTitle":892,"status":60,"phases":1160,"primaryCompletion":894,"completion":894,"start":895,"enrollment":896,"conditions":1161,"interventions":1162},[39],[898],[900,901,884],{"trials":1164,"activeCount":11},[],{"trials":1166,"activeCount":11},[],{"trials":1168,"activeCount":11},[],{"trials":1170,"activeCount":11},[],{"intervention":901,"totalTrials":84,"cells":1172},{"EARLY_PHASE1":1173,"PHASE1":1175,"PHASE2":1181,"PHASE3":1183,"PHASE4":1185,"NA":1187},{"trials":1174,"activeCount":11},[],{"trials":1176,"activeCount":11},[1177],{"nctId":891,"briefTitle":892,"status":60,"phases":1178,"primaryCompletion":894,"completion":894,"start":895,"enrollment":896,"conditions":1179,"interventions":1180},[39],[898],[900,901,884],{"trials":1182,"activeCount":11},[],{"trials":1184,"activeCount":11},[],{"trials":1186,"activeCount":11},[],{"trials":1188,"activeCount":11},[],{"intervention":1190,"totalTrials":84,"cells":1191},"EMLA Cream",{"EARLY_PHASE1":1192,"PHASE1":1194,"PHASE2":1206,"PHASE3":1208,"PHASE4":1210,"NA":1212},{"trials":1193,"activeCount":11},[],{"trials":1195,"activeCount":11},[1196],{"nctId":1197,"briefTitle":1198,"status":60,"phases":1199,"primaryCompletion":1200,"completion":1200,"start":1201,"enrollment":612,"conditions":1202,"interventions":1204},"NCT01324843","Safety and Tolerability of the Derma Vax(Trademark) Clinical Intradermal Electroporation System in Healthy Subjects",[39],"2010-05-27","2009-06-25",[1203],"Intradermal Electroporation",[1190,1205],"Aveeno Daily Moist",{"trials":1207,"activeCount":11},[],{"trials":1209,"activeCount":11},[],{"trials":1211,"activeCount":11},[],{"trials":1213,"activeCount":11},[],{"intervention":1205,"totalTrials":84,"cells":1215},{"EARLY_PHASE1":1216,"PHASE1":1218,"PHASE2":1224,"PHASE3":1226,"PHASE4":1228,"NA":1230},{"trials":1217,"activeCount":11},[],{"trials":1219,"activeCount":11},[1220],{"nctId":1197,"briefTitle":1198,"status":60,"phases":1221,"primaryCompletion":1200,"completion":1200,"start":1201,"enrollment":612,"conditions":1222,"interventions":1223},[39],[1203],[1190,1205],{"trials":1225,"activeCount":11},[],{"trials":1227,"activeCount":11},[],{"trials":1229,"activeCount":11},[],{"trials":1231,"activeCount":11},[],{"intervention":910,"totalTrials":84,"cells":1233},{"EARLY_PHASE1":1234,"PHASE1":1236,"PHASE2":1242,"PHASE3":1244,"PHASE4":1246,"NA":1248},{"trials":1235,"activeCount":11},[],{"trials":1237,"activeCount":11},[1238],{"nctId":903,"briefTitle":904,"status":60,"phases":1239,"primaryCompletion":127,"completion":127,"start":906,"enrollment":612,"conditions":1240,"interventions":1241},[39],[908],[910,911,884],{"trials":1243,"activeCount":11},[],{"trials":1245,"activeCount":11},[],{"trials":1247,"activeCount":11},[],{"trials":1249,"activeCount":11},[],{"intervention":911,"totalTrials":84,"cells":1251},{"EARLY_PHASE1":1252,"PHASE1":1254,"PHASE2":1260,"PHASE3":1262,"PHASE4":1264,"NA":1266},{"trials":1253,"activeCount":11},[],{"trials":1255,"activeCount":11},[1256],{"nctId":903,"briefTitle":904,"status":60,"phases":1257,"primaryCompletion":127,"completion":127,"start":906,"enrollment":612,"conditions":1258,"interventions":1259},[39],[908],[910,911,884],{"trials":1261,"activeCount":11},[],{"trials":1263,"activeCount":11},[],{"trials":1265,"activeCount":11},[],{"trials":1267,"activeCount":11},[],{"intervention":1269,"totalTrials":84,"cells":1270},"Oral R,R'-Fenoterol",{"EARLY_PHASE1":1271,"PHASE1":1273,"PHASE2":1286,"PHASE3":1288,"PHASE4":1290,"NA":1292},{"trials":1272,"activeCount":11},[],{"trials":1274,"activeCount":11},[1275],{"nctId":1276,"briefTitle":1277,"status":60,"phases":1278,"primaryCompletion":1279,"completion":1279,"start":1280,"enrollment":1281,"conditions":1282,"interventions":1284},"NCT01440335","Initial Study of Fenoterol as a Treatment for Heart Failure",[39],"2014-04-15","2011-07-10",29,[1283],"Congestive Heart Failure",[1269,1285],"Oral Racemic Fenoterol",{"trials":1287,"activeCount":11},[],{"trials":1289,"activeCount":11},[],{"trials":1291,"activeCount":11},[],{"trials":1293,"activeCount":11},[],{"intervention":1285,"totalTrials":84,"cells":1295},{"EARLY_PHASE1":1296,"PHASE1":1298,"PHASE2":1304,"PHASE3":1306,"PHASE4":1308,"NA":1310},{"trials":1297,"activeCount":11},[],{"trials":1299,"activeCount":11},[1300],{"nctId":1276,"briefTitle":1277,"status":60,"phases":1301,"primaryCompletion":1279,"completion":1279,"start":1280,"enrollment":1281,"conditions":1302,"interventions":1303},[39],[1283],[1269,1285],{"trials":1305,"activeCount":11},[],{"trials":1307,"activeCount":11},[],{"trials":1309,"activeCount":11},[],{"trials":1311,"activeCount":11},[],{"intervention":1313,"totalTrials":84,"cells":1314},"IV Uric Acid",{"EARLY_PHASE1":1315,"PHASE1":1317,"PHASE2":1329,"PHASE3":1331,"PHASE4":1333,"NA":1335},{"trials":1316,"activeCount":11},[],{"trials":1318,"activeCount":11},[1319],{"nctId":1320,"briefTitle":1321,"status":60,"phases":1322,"primaryCompletion":1323,"completion":1323,"start":1324,"enrollment":1325,"conditions":1326,"interventions":1327},"NCT01323335","The Relationship Between Uric Acid and Inflammatory Markers",[39],"2014-01-31","2009-03-31",97,[26],[1313,1328],"IV Rasburicase",{"trials":1330,"activeCount":11},[],{"trials":1332,"activeCount":11},[],{"trials":1334,"activeCount":11},[],{"trials":1336,"activeCount":11},[],{"intervention":1328,"totalTrials":84,"cells":1338},{"EARLY_PHASE1":1339,"PHASE1":1341,"PHASE2":1347,"PHASE3":1349,"PHASE4":1351,"NA":1353},{"trials":1340,"activeCount":11},[],{"trials":1342,"activeCount":11},[1343],{"nctId":1320,"briefTitle":1321,"status":60,"phases":1344,"primaryCompletion":1323,"completion":1323,"start":1324,"enrollment":1325,"conditions":1345,"interventions":1346},[39],[26],[1313,1328],{"trials":1348,"activeCount":11},[],{"trials":1350,"activeCount":11},[],{"trials":1352,"activeCount":11},[],{"trials":1354,"activeCount":11},[],{"intervention":618,"totalTrials":84,"cells":1356},{"EARLY_PHASE1":1357,"PHASE1":1359,"PHASE2":1365,"PHASE3":1367,"PHASE4":1369,"NA":1371},{"trials":1358,"activeCount":11},[],{"trials":1360,"activeCount":11},[1361],{"nctId":607,"briefTitle":608,"status":60,"phases":1362,"primaryCompletion":610,"start":611,"enrollment":612,"conditions":1363,"interventions":1364},[39],[614,615,616],[618,600],{"trials":1366,"activeCount":11},[],{"trials":1368,"activeCount":11},[],{"trials":1370,"activeCount":11},[],{"trials":1372,"activeCount":11},[],{"intervention":389,"totalTrials":1374,"cells":1375},3,{"EARLY_PHASE1":1376,"PHASE1":1378,"PHASE2":1380,"PHASE3":1382,"PHASE4":1397,"NA":1399},{"trials":1377,"activeCount":11},[],{"trials":1379,"activeCount":11},[],{"trials":1381,"activeCount":11},[],{"trials":1383,"activeCount":11},[1384,1393],{"nctId":1385,"briefTitle":1386,"status":60,"phases":1387,"primaryCompletion":1388,"completion":1388,"start":1389,"enrollment":1390,"conditions":1391,"interventions":1392},"NCT00000177","Estrogen Hormone Protocol",[41],"1999-01","1995-10",120,[21],[389],{"nctId":382,"briefTitle":383,"status":60,"phases":1394,"primaryCompletion":385,"completion":385,"conditions":1395,"interventions":1396},[41],[21,387],[389,371],{"trials":1398,"activeCount":11},[],{"trials":1400,"activeCount":11},[1401],{"nctId":1402,"briefTitle":1403,"status":585,"phases":1404,"primaryCompletion":170,"completion":170,"conditions":1405,"interventions":1407},"NCT00000175","The Effects of Sex Hormones on Cognition and Mood in Older Adults",[43],[77,1406],"Mood Disorders",[389,1408],"Testosterone",{"intervention":1410,"totalTrials":47,"cells":1411},"pioglitazone",{"EARLY_PHASE1":1412,"PHASE1":1414,"PHASE2":1416,"PHASE3":1427,"PHASE4":1429,"NA":1431},{"trials":1413,"activeCount":11},[],{"trials":1415,"activeCount":11},[],{"trials":1417,"activeCount":11},[1418],{"nctId":1419,"briefTitle":1420,"status":60,"phases":1421,"primaryCompletion":1422,"completion":1422,"start":1423,"enrollment":1424,"conditions":1425,"interventions":1426},"NCT00982202","Pioglitazone in Alzheimer Disease",[40],"2005-01","2002-01",25,[21],[1410],{"trials":1428,"activeCount":11},[],{"trials":1430,"activeCount":11},[],{"trials":1432,"activeCount":11},[1433],{"nctId":1434,"briefTitle":1435,"status":585,"phases":1436,"primaryCompletion":127,"completion":127,"start":1437,"enrollment":84,"conditions":1438,"interventions":1440},"NCT00743327","Androgen Deprivation Therapy Study",[],"2008-10",[787,1439,35,339],"Metabolic Syndrome",[1441],"Pioglitazone",{"intervention":1408,"totalTrials":47,"cells":1443},{"EARLY_PHASE1":1444,"PHASE1":1446,"PHASE2":1448,"PHASE3":1450,"PHASE4":1452,"NA":1463},{"trials":1445,"activeCount":11},[],{"trials":1447,"activeCount":11},[],{"trials":1449,"activeCount":11},[],{"trials":1451,"activeCount":11},[],{"trials":1453,"activeCount":11},[1454],{"nctId":1455,"briefTitle":1456,"status":60,"phases":1457,"primaryCompletion":73,"completion":73,"start":1458,"enrollment":1459,"conditions":1460,"interventions":1461},"NCT00182871","Testosterone Effects on Bone and Frailty",[42],"2001-11",140,[15,678,337],[1462],"testosterone",{"trials":1464,"activeCount":11},[1465],{"nctId":1402,"briefTitle":1403,"status":585,"phases":1466,"primaryCompletion":170,"completion":170,"conditions":1467,"interventions":1468},[43],[77,1406],[389,1408],{"intervention":1470,"totalTrials":47,"cells":1471},"DHEA",{"EARLY_PHASE1":1472,"PHASE1":1474,"PHASE2":1476,"PHASE3":1478,"PHASE4":1480,"NA":1482},{"trials":1473,"activeCount":11},[],{"trials":1475,"activeCount":11},[],{"trials":1477,"activeCount":11},[],{"trials":1479,"activeCount":11},[],{"trials":1481,"activeCount":11},[],{"trials":1483,"activeCount":11},[1484,1493],{"nctId":1485,"briefTitle":1486,"status":60,"phases":1487,"primaryCompletion":1488,"completion":1488,"start":1489,"enrollment":1490,"conditions":1491,"interventions":1492},"NCT00111930","Biological Effects of Dehydroepiandrosterone (DHEA) in the Elderly",[43],"2005-03","2000-08",144,[908],[1470],{"nctId":1494,"briefTitle":1495,"status":60,"phases":1496,"primaryCompletion":1497,"completion":1497,"start":1498,"enrollment":1499,"conditions":1500,"interventions":1502},"NCT00099697","Biologic Effects of Dehydroepiandrosterone (DHEA) in Humans",[43],"2004-02","2001-06",56,[15,23,1501],"Insulin Resistance",[1470],{"intervention":1504,"totalTrials":84,"cells":1505},"zolpidem",{"EARLY_PHASE1":1506,"PHASE1":1508,"PHASE2":1510,"PHASE3":1512,"PHASE4":1514,"NA":1516},{"trials":1507,"activeCount":11},[],{"trials":1509,"activeCount":11},[],{"trials":1511,"activeCount":11},[],{"trials":1513,"activeCount":11},[],{"trials":1515,"activeCount":11},[],{"trials":1517,"activeCount":11},[1518],{"nctId":1519,"briefTitle":1520,"status":60,"phases":1521,"start":588,"enrollment":612,"conditions":1522,"interventions":1525},"NCT00383357","Sleepiness and the Risk of Falling",[43],[15,1523,1524],"Balance","Sleep",[1504],{"intervention":1527,"totalTrials":84,"cells":1528},"Iron Supplement, 120mg",{"EARLY_PHASE1":1529,"PHASE1":1531,"PHASE2":1533,"PHASE3":1535,"PHASE4":1537,"NA":1539},{"trials":1530,"activeCount":11},[],{"trials":1532,"activeCount":11},[],{"trials":1534,"activeCount":11},[],{"trials":1536,"activeCount":11},[],{"trials":1538,"activeCount":11},[],{"trials":1540,"activeCount":11},[1541],{"nctId":1542,"briefTitle":1543,"status":60,"phases":1544,"primaryCompletion":73,"completion":73,"start":1423,"enrollment":1545,"conditions":1546,"interventions":1547},"NCT00094042","Work and Iron Status Evaluation",[43],16000,[15],[1527],{"intervention":1549,"totalTrials":84,"cells":1550},"fenofibrate",{"EARLY_PHASE1":1551,"PHASE1":1553,"PHASE2":1555,"PHASE3":1557,"PHASE4":1559,"NA":1561},{"trials":1552,"activeCount":11},[],{"trials":1554,"activeCount":11},[],{"trials":1556,"activeCount":11},[],{"trials":1558,"activeCount":11},[],{"trials":1560,"activeCount":11},[],{"trials":1562,"activeCount":11},[1563],{"nctId":1564,"briefTitle":1565,"status":99,"phases":1566,"primaryCompletion":1567,"completion":1567,"start":1048,"enrollment":172,"conditions":1568,"interventions":1570},"NCT00627653","Effect of a PPAR-Alpha Agonist on the Age Related Changes in Myocardial Metabolism and Mechanical Function",[43],"2009-12",[1569],"Cardiovascular Diseases",[1549],{"intervention":1572,"totalTrials":84,"cells":1573},"Hormone Replacement Therapy",{"EARLY_PHASE1":1574,"PHASE1":1576,"PHASE2":1578,"PHASE3":1580,"PHASE4":1582,"NA":1584},{"trials":1575,"activeCount":11},[],{"trials":1577,"activeCount":11},[],{"trials":1579,"activeCount":11},[],{"trials":1581,"activeCount":11},[],{"trials":1583,"activeCount":11},[],{"trials":1585,"activeCount":11},[1586],{"nctId":1587,"briefTitle":1588,"status":60,"phases":1589,"primaryCompletion":1590,"completion":1590,"start":1591,"enrollment":1592,"conditions":1593,"interventions":1596},"NCT00061711","Alternative Therapies for Menopause: A Randomized Trial",[43],"2005-12","2000-07",355,[1594,1595],"Menopause","Hot Flashes",[1572,1597,1598],"Cimicifuga racemosa","Multibotanical phytoestrogen formula",{"intervention":1597,"totalTrials":84,"cells":1600},{"EARLY_PHASE1":1601,"PHASE1":1603,"PHASE2":1605,"PHASE3":1607,"PHASE4":1609,"NA":1611},{"trials":1602,"activeCount":11},[],{"trials":1604,"activeCount":11},[],{"trials":1606,"activeCount":11},[],{"trials":1608,"activeCount":11},[],{"trials":1610,"activeCount":11},[],{"trials":1612,"activeCount":11},[1613],{"nctId":1587,"briefTitle":1588,"status":60,"phases":1614,"primaryCompletion":1590,"completion":1590,"start":1591,"enrollment":1592,"conditions":1615,"interventions":1616},[43],[1594,1595],[1572,1597,1598],{"intervention":1598,"totalTrials":84,"cells":1618},{"EARLY_PHASE1":1619,"PHASE1":1621,"PHASE2":1623,"PHASE3":1625,"PHASE4":1627,"NA":1629},{"trials":1620,"activeCount":11},[],{"trials":1622,"activeCount":11},[],{"trials":1624,"activeCount":11},[],{"trials":1626,"activeCount":11},[],{"trials":1628,"activeCount":11},[],{"trials":1630,"activeCount":11},[1631],{"nctId":1587,"briefTitle":1588,"status":60,"phases":1632,"primaryCompletion":1590,"completion":1590,"start":1591,"enrollment":1592,"conditions":1633,"interventions":1634},[43],[1594,1595],[1572,1597,1598]]